T-Cell Immunotherapies: The Goldrush Continues
The cancer therapeutics market is considered to be one of the most active segments within the pharmaceutical industry. In the past five years, the USFDA has approved more than 100 drugs for the treatment of different types of cancer. According to the International Agency for Research on Cancer (IARC), close to 17 million new cases of cancer were diagnosed in 2018, worldwide. By 2040, it is estimated that the aforementioned number is likely to grow to 27.5 million. In fact, the global cancer burden is anticipated to increase by 70% in the next 20 years.
I have highlighted below some of the most interesting insights from our study. You can also access additional details here.
Eminent representatives from different pharmaceutical companies and academic institutes confirm the growing interest in T-cell immunotherapies
Exponential increase in the number of tweets, and the growing optimism of both industry and non-industry stakeholders, indicate the sustained interest in this growing field
With two approved therapies and close to 650 clinical / preclinical product candidates, the T-cell immunotherapy pipeline has evolved significantly over the past few years
Many novel, disease-specific targets have been discovered and are being investigated for use in the treatment of a diverse range of oncological indications by therapy developers across the world
In the last 10 years, over 450 clinical trials, evaluating various types of CAR-T therapies, were registered across different geographies; interestingly, over 50% of these are trials are being conducted in China
Specifically, for CAR-T cell therapies, extensive efforts are underway to improve the CAR constructs across successive generations, involving alterations in the scFv region and using different types of gene delivery vectors
A large number of prominent scientists from renowned academic and research institutes, acting as key opinion leaders, have led the clinical development efforts in this domain
Case Study: Over time, CMOs offering manufacturing services for different types of T-Cell cell-based therapies have become an indispensable part of the biopharmaceutical supply chain
Several investors, having realized the opportunity within this upcoming segment of cancer immunotherapy, have invested over USD 13 billion, across 200+ instances, in the period between 2000 and 2019
With a promising development pipeline and encouraging clinical results, the market is anticipated to witness an annualized growth rate of over 40% during the next decade
As new blockbuster therapies emerge, we expect the market to spread across different geographical regions; several key / emerging players will tap the growing opportunity
In order to fully monetize the promise, companies are actively deploying diverse promotional strategies for their respective products
To learn more, please click here. For any queries / suggestions, please do not hesitate to contact us at firstname.lastname@example.org. Alternatively, you can place an Order by filling this Order Form.